{"product_id":"how-to-comply-with-drug-cathy-l-burgess-9781935065838","title":"How to Comply with Drug CGMPs","description":"\u003cp\u003eGlobalization in the pharmaceutical industry, expanded FDA authority over CGMPs, and increased scrutiny of data integrity, among other developments in this rapidly evolving field, make for a complex compliance environment.\u003c\/p\u003e\u003cp\u003eThis resource provides the legal community and regulated industry with a concise reference on the compliance standards and governing principles for current Good Manufacturing Practices.\u003c\/p\u003e\u003cp\u003eEven as these standards will change over time, the underlying concepts discussed will help the reader understand these changes, and how to incorporate them into a robust compliance program.\u003c\/p\u003e\u003cp\u003eTable of Contents\u003cbr\u003e Introduction \u003cbr\u003e I. What Are CGMPs? \u003cbr\u003e A. Principles\u003cbr\u003e B. Legal Framework\u003cbr\u003e C. FDA Guidance to Industry\u003cbr\u003e II How Does FDA Evaluate CGMP Compliance?\u003cbr\u003e A. Establishment Inspections\u003cbr\u003e B. Samples\u003cbr\u003e C. Field Alert Reports\u003cbr\u003e D. Adverse Event Reports and Consumer Complaints\u003cbr\u003e E. Risk-Based Selection of Sites and Inspection Frequency\/Rigor\u003cbr\u003e F. Regulation of CGMPs for OTC Monograph and Homeopathic Drugs\u003cbr\u003e III What Are the Consequences of Noncompliance? \u003cbr\u003e A. Advisory Actions: Warning Letters, Untitled Letters and Regulatory Meetings\u003cbr\u003e B. Import Detentions and Import Alerts\u003cbr\u003e C. Recalls\u003cbr\u003e D. Seizures\u003cbr\u003e E. Injunctions\u003cbr\u003e F. Criminal Prosecutions\u003cbr\u003e G. False Claims Act and Qui Tam Investigations\u003cbr\u003e H. Other Consequences\u003cbr\u003e I. Certificates of Export\/Government Contracts\u003cbr\u003e J. Application Disapproval\/Revocation\u003cbr\u003e K. Application Integrity Policy\u003c\/p\u003e\u003cp\u003eIV Recent CGMP Enforcement Activity \u003cbr\u003e A. The Pattern of Enforcement\u003cbr\u003e B. GlaxoSmithKline, PLC and its Subsidiary SB Pharmco Puerto Rico Inc.\u003cbr\u003e C. Genzyme Corporation\u003cbr\u003e D. Ranbaxy Laboratories Limited and its Subsidiary Ranbaxy USA Inc.\u003cbr\u003e V How Do We Remain \"Current\" with CGMPs?\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Cathy L. Burgess, Daniel G. Jarcho\u003cbr\u003e\u003cb\u003eISBN-10:\u003c\/b\u003e 1935065831\u003cbr\u003e\u003cb\u003eISBN-13:\u003c\/b\u003e 9781935065838\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Food and Drug Law Institute\u003cbr\u003e\u003cb\u003eLanguage:\u003c\/b\u003e English\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 04\/26\/2017\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 102\u003cbr\u003e\u003cb\u003eFormat:\u003c\/b\u003e Paperback\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 0.57lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 11.00h x 8.50w x 0.21d","brand":"Cathy L. Burgess","offers":[{"title":"Paperback","offer_id":44125595599103,"sku":"9781935065838","price":199.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/2982\/9887\/files\/img_9b31e6d1-cafb-4832-82ff-d296b27e6f7b.jpg?v=1687443506","url":"https:\/\/www.whiterainbookhouse.com\/products\/how-to-comply-with-drug-cathy-l-burgess-9781935065838","provider":"WR Book House","version":"1.0","type":"link"}